Literature DB >> 16130896

Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen.

Shusei Ikegami1, Takushi Tadakuma, Kazuo Yamakami, Takeshi Ono, Satoshi Suzuki, Ichiro Yoshimura, Tomohiko Asano, Masamichi Hayakawa.   

Abstract

Prostate cancer cells express prostate-specific membrane antigen (PSMA). We developed an IgM type monoclonal antibody against PSMA. The antibody was coupled to poly-L-lysine and thereafter this conjugate was mixed with cationic liposomes containing plasmid DNA. The antibody-liposome complex was tested whether it could deliver the gene of interest selectively to the PSMA positive cells. As assessed by beta-galactosidase reporter gene, the transfection efficiency was 13.2% with anti-PSMA-liposome complex as compared to 4% with control IgM liposome complex. In contrast, no such differences were observed in PSMA negative PC-3, DU145 and T24 cells. Furthermore, in the suicide gene therapy in vitro with thymidine kinase gene plus ganciclovir system, anti-PSMA liposome complex demonstrated a selective growth inhibitory effect on PSMA positive LNCaP cells but not on PSMA negative cell lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16130896     DOI: 10.1111/j.1749-0774.2005.tb00053.x

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  20 in total

1.  Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate.

Authors:  S K Yoon; L Mohr; C R O'Riordan; A Lachapelle; D Armentano; J R Wands
Journal:  Biochem Biophys Res Commun       Date:  2000-06-07       Impact factor: 3.575

2.  Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization.

Authors:  M Kawakami; J Nakayama
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

3.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.

Authors:  G L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; P F Schellhammer; R Moriarty
Journal:  Urology       Date:  1996-08       Impact factor: 2.649

4.  Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Authors:  John P Leonard; Morton Coleman; Jamie C Ketas; Amy Chadburn; Richard Furman; Michael W Schuster; Eric J Feldman; Michelle Ashe; Stephen J Schuster; William A Wegener; Hans J Hansen; Heather Ziccardi; Michael Eschenberg; Urte Gayko; Scott Z Fields; Alessandra Cesano; David M Goldenberg
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

5.  Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer.

Authors:  Shusei Ikegami; Takushi Tadakuma; Takeshi Ono; Satoshi Suzuki; Ichiro Yoshimura; Tomohiko Asano; Masamichi Hayakawa
Journal:  Cancer Sci       Date:  2004-04       Impact factor: 6.716

6.  Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Authors:  Guido Bocci; Shan Man; Shane K Green; Giulio Francia; John M L Ebos; Jeanne M du Manoir; Adina Weinerman; Urban Emmenegger; Li Ma; Philip Thorpe; Andrew Davidoff; James Huber; Daniel J Hicklin; Robert S Kerbel
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  Expression of the prostate-specific membrane antigen.

Authors:  R S Israeli; C T Powell; J G Corr; W R Fair; W D Heston
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Prostate-specific membrane antigen expression in normal and malignant human tissues.

Authors:  D A Silver; I Pellicer; W R Fair; W D Heston; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

9.  Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition.

Authors:  Shusei Ikegami; Takushi Tadakuma; Satoshi Suzuki; Ichiro Yoshimura; Tomohiko Asano; Masamichi Hayakawa
Journal:  Jpn J Cancer Res       Date:  2002-10

10.  Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.

Authors:  Christoph Volpers; Christian Thirion; Volker Biermann; Stefanie Hussmann; Helmut Kewes; Patrick Dunant; Helga von der Mark; Andreas Herrmann; Stefan Kochanek; Hanns Lochmüller
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.